Reports Q2 revenue $1.24B, consensus $1.19B. “I’d like to thank our global Elanco (ELAN) team for delivering our 8th straight quarter of growth, driving results beyond expectations,” said Jeff Simmons, president and CEO of Elanco. “Our diverse portfolio of innovation fueled accelerating organic constant currency revenue growth of 8%, led by U.S. Pet Health at 11%. We have once again increased our innovation revenue target, reflecting contributions by Credelio Quattro, Experior, AdTab, and Zenrelia, which also are stabilizing our base portfolio. We are delevering faster than expected, reaching 4.0x at quarter-end, and have improved our 2025 net leverage ratio target. With our strong first half performance and consistent execution, we are raising our full-year outlook, even while recognizing a highly dynamic landscape with a mix of opportunities and challenges. We enter the balance of the year well-positioned to deliver our commitments, transform animal care, and create long-term shareholder value. Elanco is focused on executing with high engagement and discipline, which we expect to drive sustained growth, innovation, and cash.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Notable companies reporting before tomorrow’s open
- Elanco announces European Commission approval of Zenrelia
- Elanco price target raised to $18 from $17 at UBS
- Starbucks downgraded, Oracle initiated: Wall Street’s top analyst calls
- Leerink upgrades Elanco following channel checks, semiannual veterinarian survey